Arcutis Biotherapeutics, Inc. (ARQT) delivered a return of 91.73% over the past year. Since ARQT does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Arcutis Biotherapeutics, Inc. one year ago would be worth $19,173 today, representing a gain of $9,173.

Arcutis Biotherapeutics, Inc. (ARQT) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ARQT, the total return equals the price-only return.

Yes, Arcutis Biotherapeutics, Inc. (ARQT) outperformed the S&P 500 by 66.74 percentage points over the past year. ARQT delivered a total return of 91.73%, compared to the S&P 500's 24.99%. This 66.74pp alpha means investors in ARQT earned more than a passive S&P 500 index fund.

Arcutis Biotherapeutics, Inc. (ARQT) experienced a maximum drawdown of -37.50% over the past year, declining from its peak on 2025-12-05 to its trough on 2026-05-19. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Arcutis Biotherapeutics, Inc. (ARQT)'s long-term returns with dividends reinvested. Over 10 years, the total return is 20.2% (1.9% CAGR) — $10,000 would have grown to $12,023. Over 20 years: 20.2% total return (0.9% CAGR) — $10,000 → $12,023. Over 30 years: 20.2% total return (0.6% CAGR) — $10,000 → $12,023. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Arcutis Biotherapeutics, Inc.'s best calendar year was 2024 with a total return of 306.1%. Its worst year was 2023 with a total return of -78.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 384.3 percentage points.